Born in 1975, graduated from the medical school in Aarhus, Denmark in 2003. Since then clinical training and specialisation in hepatology, alongside training in clinical epidemiology. I have published more than 100 papers, most of them in the field of hepato-epidemiology. I currently do half-time clinical work, half-time research. My primary interests are alcoholic liver disease and hepatocellular carcinoma, most notably the value of surveillance for hepatocellular carcinoma among patients with alcoholic cirrhosis.

Pietro Fiocchi is a member of the European Parliament. He is also an Italian Entrepreneur and politician. After graduating in aerospace engineering at the University of Missouri of Rolla, in 1990 he entered the Navy, serving as a Sub-lieutenant on the San Giorgio landing ship until 1992 and working with the San Marco Battalion and with the Comsubin, an Italian special forces department. After two years in the navy he began his professional activity as technical director at Ravasi Robotics, an Italian robotics company, and later as manager and technical director at Fiocchi Munizioni. In 1998 he became president and member of the board of directors of Fiocchi of America. In 2007 he founded Fiocchi UK, while in 2015 he became a member of the Board of Directors of Target, a New Zealand company producing hunting and shooting cartridges. In 2019 he has been elected as a member of the European Parliament on the Brothers of Italy list. He is member of the Special Committee on Beating Cancer, of the Committee on the Environment, Public Health and Food Safety and substitute to the Committee on Industry, Research and Energy.

Frances Fitzgerald is a Fine Gael MEP for Dublin City and County. She is a member of the ECON (Economic & Monetary Affairs) Committee, FEMM (Women’s Rights & Gender Equality) Committee and DEVE (Development) Committee. Frances also serves as the lead coordinator for the European People’s Party on FEMM. Prior to her election to the European Parliament in the 2019 European Elections, Frances served as a Fine Gael Parliamentarian for over 20 years. She served as a Senator and T.D. in Dublin Mid-West (2007-2019) and has previously served as a Fine Gael T.D. in Dublin South East (1992-2002). She most recently served as Tánaiste (2016-17), one of only four women to have ever held this position. She has also served as Minister for Business, Enterprise & Innovation (2017); Minister for Justice & Equality (2014-17) and was the State’s first Minister for Children & Youth Affairs (2011-14). Frances has a clear record of delivering change and reform in Ireland stemming back to her education and early career. Raised in Stillorgan, she was educated in Dominican College Sion Hill, Blackrock and the London School of Economics. She worked as a social worker and family therapist for ten years in Ballymun Child & Family Centre and in St. Ultan’s Children’s Hospital, St. James’ Hospital and the Mater Hospital. She has also worked in inner city communities in both Dublin and London.

Prof. Frank Murray is Consultant Hepatologist/Gastroenterologist at Beaumont Hospital, Dublin and Associate Professor of Medicine at the Royal College of Surgeons in Ireland and EASL Policy and Public Health Committee Member. He graduated from University College Dublin in 1980 and trained in Dublin, Boston USA, and Nottingham, England. He was previously Consultant Gastroenterologist in Ninewells Hospital and Medical School, Dundee, Scotland. Prof. Frank Murray became a a Fellow of the Royal College of Physicians of Ireland in 1994, was elected to the Council in 2002, and was appointed Registrar in 2007. He was the 141st President of the Royal College of Physicians of Ireland from 2014-2017. Prof. Murray is also the former chair of both the Basic Specialist Training Committee and the Irish Committee on Higher Medical Training. He is a founding member of the RCPI/HSE EQUALS Initiative, a group which sources decommissioned medical equipment in Irish hospitals to send to hospitals in less developed countries and is partnering the development of Post-graduate Training in Zambia. Prof. Murray is Chairman of the RCPI Policy Group on Alcohol in 2102 , and Chairman of Alcohol Health Alliance Ireland in 2015. He has played a prominent national role in highlighting alcohol harm in Ireland and supported the introduction of evidence-based alcohol counter-measures, such as those in the Public health Alcohol Bill. Prof. Murray has recently been appointed Director, National Doctors Training and Planning (NDTP), HSE in Dublin.

Rachel Halford is CEO at The Hepatitis C Trust and part of the Board of Directors of Liver Patients International. She has over 20 years’ experience of working with people at high-risk of viral hepatitis, and liver disease generally – the homeless, prisoners, substance users and migrants. The past 15 years of which have been in senior management roles within the voluntary/ NGO sector. Passionate about equality and human rights, Rachel joined The Hepatitis C Trust in 2015 as Deputy CEO, before this she was CEO of Women in Prison, a national UK campaigning organisation that provided support and advocacy for women affected by the criminal justice system. Over the last year Rachel’s work has included working with NHS England Health and Justice setting up and delivering a Prison Peer project across the London prison estate to support the implementation of a national BBV Opt Out policy jointly developed by National Offender Management, Public Health England and NHS England. Diagnosed with Hepatitis C in 1998, Rachel completed Interferon treatment in 2007 clearing the disease.

Marko Korenjak is the president of European Liver Patients Association (ELPA) and president of Slovenian Association for patients with viral hepatitis - Slovenija HEP. He holds a Master’s degree in International Relations, a second Master’s degree in Business and Economics, and is certified as international NLP Trainer and NLP Coach. He is closely involved in the development of ELPA strategy plan, ELPA work plan and budget, ELPA fundraising activities and ELPA Symposium preparation at International Liver Congress™ organised by EASL. He works in ELPA Horizon2020 activities as project leader of dissemination and communication of the project LIVERHOPE, project MICROB-PREDICT, project GALAXY, and also in the project EIT LIVERSCREEN funded by the European Institute for Innovation and Technology – section for Health. Marko is a member of the steering committee and trainer at ELPA University was a representative of ELPA in NoHEP movement for Europe. He is a member of EASL, International Communication Association (ICA), and International NLP Trainer Association (INLPTA).

Jeffrey V. Lazarus (Ph.D., MIH, MA) is a Member of the EASL Policy and Public Health Committee. He holds positions as an associate research professor at the Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, where he leads the health systems research team, as Associate Professor at the Faculty of Medicine, University of Barcelona, Spain and as a senior scholar at the CUNY Graduate School of Public Health and Policy in New York City. His decade-long career as health systems, HIV, and viral hepatitis expert at WHO Europe was followed by three years (2009-2012) as a senior specialist at the Global Fund to Fight AIDS, Tuberculosis, and Malaria, three years as director of Health Systems Global (2012-15) then board chair of the foundation AFEW International (2015-18). Prof Lazarus is now Vice-Chairman of the board of the EASL International Liver Foundation, where he developed the micro-elimination approach to HCV elimination. He is also a member of the INHSU international education committee and co-chair of the HIV Outcomes Beyond Viral Suppression coalition. He is the author of more than 300 publications and his current scientific work includes leading the Hep C Free Baleares, HBV COMSAVA, and Copenhagen T'n'T studies, and the Global COVID-19 consensus statement on ending the pandemic. He is a core member of The Lancet GastroHep Commission on Viral Hepatitis, a co-author of the Lancet COVID-19 commission and a commissioner of the EASL-Lancet European Liver Commission and The Lancet-IAPAC HIV Commission. At AME/VE he is chair of the NAFLD models of care workshop, on the organizing committee of COLDA, and on the scientific committee of IVHEM.

Dr Kremlin Wickramasinghe is acting Head of the WHO European Office for Prevention and Control of Noncommunicable Diseases (NCD Office) and Regional Adviser for Nutrition, Physical Activity and Obesity. Prior to this position, he worked as a technical officer on Noncommunicable Diseases (NCD) Risk Factors, since 2017 in the same office. Before joining WHO, he was the co-director of the WHO Collaborating Centre on Population Approaches to NCD Prevention at the University of Oxford, United Kingdom. He co-edited the text book “An Introduction to Population-level Prevention of Non-Communicable Diseases” published by the Oxford University Press. He has a special interest in multisectoral responses to health promotion, quantifying the outcome of health policies and implementation research. Kremlin graduated as a medical doctor with MBBS from the University of Colombo. He holds an MSc in Global Health Science and a DPhil (PhD) in Public Health from the University of Oxford.

Dr Jennifer L. Baker is a Senior Researcher and leads a team in Lifecourse Epidemiology at the Center for Clinical Research and Prevention, Copenhagen University Hospital in Denmark. The focus of her research program is on the causes and the short- and long-term consequences of body size and growth in childhood, with a particular emphasis on obesity in childhood. She is an expert in conducting studies using large population based cohorts linked with nationwide registers of health data. Dr. Baker is a member of the European Association for the Study of Obesity (EASO) executive committee and is the co-chair of its Childhood Obesity Task Force. She is also active in the BioMed Alliance Health Data Taskforce on behalf of EASO.

Tomislav Sokol is a Croatian politician currently serving as a Member of the European Parliament for the Croatian Democratic Union since 2019. Sokol became a Member of the European Parliament in the 2019 election. He has since been serving on the Committee on the Internal Market and Consumer Protection. In 2022, he also joined the Special Committee on the COVID-19 pandemic. Also since 2022, he has been the parliament’s ENVI rapporteur on the European Commission’s proposal for a European Health Data Space. In addition to his committee assignments, Sokol is part of the Parliament's delegation to the EU-Turkey Joint Parliamentary Committee. He is also a member of the European Parliament Intergroup on Seas, Rivers, Islands and Coastal Areas and the MEPs Against Cancer group.

Prof. Zelber-Sagi is a clinical dietitian, epidemiologist and a researcher in nutritional epidemiology. She holds a BSc in nutrition sciences at the Hebrew University and a PhD in epidemiology and preventive medicine at the Sackler School of Medicine at Tel Aviv University. Currently, Prof Zelber-Sagi is the Head of School of Public Health, University of Haifa. She also works as a clinical dietitian at the liver Unit of the Tel-Aviv hospital. She is a member of the “National Committee for Nutrition, Gastroenterology and Liver Disease” and Head of the “Gastroenterology and Hepatology Nutrition forum” on behalf of The Israeli Nutrition Association. She is also a member of UEG’s Public Affairs Committee and former member of the EASL’s Policy and Public Health Committee. Her research deals mainly with non-alcoholic fatty liver disease (NAFLD) epidemiology, prevention and treatment.

Sirpa Pietikäinen is a Finnish politician and Member of the European Parliament (MEP) from Finland. She is a member of the National Coalition Party, part of the European People's Party. She has been a Member of the European Parliament (MEP) since 2008, and was re-elected in 2009 and 2014. She is member of the MEP Friends of the Liver group. Pietikäinen has an MBA degree from Helsinki School of Economics. She has received The Knight Commander's Order of the White Rose of Finland (1993).

Mojca Matičič, EASL Policy and Public Health Committee Member (2018-2022), is Head of the Viral Hepatitis Unit and Head of the STI Outpatient Service at the Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre in Ljubljana, Slovenia. She is also a Full Professor of Infectious Diseases and Epidemiology at the Faculty of Medicine, University of Ljubljana. After gaining her medical degree, Professor Matičič specialised in internal medicine and in infectious diseases at the University of Ljubljana, before completing a masters and PhD in HIV/AIDS and HCV, respectively. Subsequently, she undertook international postdoctoral training at the Middlesex Hospital and Royal Free Hospital in London, UK. Professor Matičič’s research interests focus on viral infections, primarily viral hepatitis, antiviral treatment and STIs. An active member of numerous professional societies including EASL (European association for the Study of the Liver), where she is a member of the Policy and Public Health Committee (PPHC), Hepatitis B&C Public Policy Association (HepB&C PPA), ESCMID (European Society of Clinical Microbiology and Infectious Diseases), and INHSU (International Network for management of Hepatitis in Substance Users), she currently leads a hepatitis C study group at C-EHRN (Correlation-European Harm Reduction Network), serves as an advisor to WHO (World Health Organization) Europe, ECDC (European Center for Disease Control) and the VHPB (Viral Hepatitis Prevention Board). Professor Matičič is also a member of the HIV/AIDS Committee of the Slovene Ministry of Health and a co-author of the National Strategy for the Management of HCV Infection in Slovenia (1997). She leads the Slovene National Viral Hepatitis Expert Board and co-authored the national clinical practice guidelines for the treatment of HCV and HBV infections. She has authored or co-authored more than 450 articles in national and international peer-reviewed journals, EASL Policy and Position statements and organised numerous national and international conferences.

Sara Cerdas is a Portuguese medical doctor and since July of 2019 a Member of European Parliament. She is member on the Committee on the Environment, Public Health and Food Safety and substitute member on the Committee on Transport and Tourism. She is also member of the special committee on beating cancer and the S&D shadow rapporteur for the EU4Health Programme. Sara Cerdas is co-chair in the European Parliament's Working Group on Health, which brings to discussion European health issues with stakeholders and experts. She holds a master's degree in Medicine from the University of Lisbon, a master's degree in Public Health from the University of Umeå and is a doctoral student in Public Health Sciences from the University of Stockholm. During her career, she had work in the Epidemiology Department of Portuguese Health National Institute and in The Public Health Emergency Centre of the Portuguese Directorate-General of Health, having an active participation in tackling regional and national outbreaks.

Maria Buti is currently Professor of Medicine and consultant of Hepatology at the Hospital General Universitari Valle Hebron, Barcelona and the EASL Public Health Councillor. Dr Buti has worked in viral hepatitis for the last 35 years, particularly in diagnosis and therapy of hepatitis B , C and D. She has published more than 500 papers the field of liver disease, with numerous papers and contributions to books.

Dr Norah Terrault is the Chief of Gastroenterology & Hepatology at Keck Medical Center of USC and the President of the American Association for the Study of Liver Diseases (AASLD). She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation. She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines.

Dr Mario Pessoa is an Assistant-Professor at Division of Gastroenterology and Hepatology at University of São Paulo School of Medicine - HCFMUSP. He coordinates the Medical Residency of Clinical Gastroenterology and Hepatology. Dr Pessoa equally works as an Associate Editor of Liver International and Current Hepatitis Reports. He is the Vice President at the Latin American Association for the Study of the Liver (ALEH) and a member of the Brazilian Society of Hepatology as well as the Paulista Association of the Study of the Liver.

Professor Manal El Sayed is Professor of Pediatrics at Ain Shams University and the Co-Chair of the Society on Liver Disease Africa (SOLDA). She is the clinical director of the national HCV Pediatric treatment program and the director of the clinical research unit and co-supervisor of the viral hepatitis treatment center at Ain Shams University. Manal is a founding member of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH) charged with planning and implementing the nationwide program for prevention and management of viral hepatitis since 2006. Manal is also an active board member and secretary general of the Egyptian Liver Care Society.

Marko Korenjak is the President of European Liver Patients Association (ELPA) and president of Slovenian Association for patients with viral hepatitis - Slovenija HEP. He is a member of EASL, International Communication Association (ICA), and International NLP Trainer Association (INLPTA). In 2014 he wrote a book about his fight against hepatitis C with the title, 336 Days of Hope. In 2017 he was selected by Economist Intelligence Unit as one of 18 most influential individuals and/or organisations in the fight against hepatitis C.

Patrizia Burra is Associate Professor of Gastroenterology and Head of Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology at the Padua University Hospital, Italy. Patrizia Burra is internationally recognized as an expert in hepatology and liver transplantation. She is the current Public Affairs Group Chair at United European Gastroenterology (UEG) and the Past President of the International Liver Transplant Society (ILTS). She has authored more than 280 articles in international peer-reviewed journals, with an H-index of 46.

Donna R. Cryer, JD, she is the founder and CEO of Global Liver Institute (GLI). She received a life-saving liver transplant in law school after years of living with an autoimmune disease. On the 20th anniversary of her transplant, she realized her experience as a patient, lawyer, and professional health systems consultant could help fellow patients. In 2014, she founded Global Liver Institute. She is widely recognized as an expert on the topics of patient engagement in research, digital health, and high-value equitable care.

Prof. Loreta Kondili is a specialist in Gastroenterology and Digestive Endoscopy since 2005 and earned her Ph.D. degree in 2015. She is trained in Sapienza University and Policlinico Umberto 1- Rome and in the Liver Unit of Queen Elisabeth Hospital/ University of Birmingham (UK). She is a Clinical Researcher at the Center for Global Health, Istituto Superiore di Sanità, Rome. Prof. Kondili has worked in viral hepatitis and liver diseases for the last 25 years, and her main research areas focus on epidemiological, clinical, and therapy of chronic viral liver disease. She has been involved in the scientific coordination of several Italian Networks in the field of chronic liver disease of different etiologies with specific regard to chronic viral hepatitis, liver cirrhosis, and its complications. She is currently the principal investigator of the Italian Platform for the study of Viral Hepatitis Therapies (PITER). She has strong competencies in the Health Technology Assessment and management and analysis of real-life big databases. She has collaborated with the Center for Economic and International Studies (CEIS) of the Tor Vergata University of Rome and the Center for Disease Analysis Colorado (USA), for the definition of the HCV elimination strategies in Italy as a goal of the World Health Organization. She is currently serving as expert for the Italian Ministry of Health on the implementation of the National Hepatitis plan. She has been an expert of the Italian Drug Agency (AIFA) and is currently serving as expert at European Medicines Agency (EMA) She is a Professor of Medicine at the University of Tirana. She passed the National Scientific Qualification as Associated Professor (Bando D.D. 1532/2016 Settore concorsuale 06/D4 Fascia: II). She holds a 2nd level master’s in Evaluation and Management of Health Technologies from the Catholic University of Rome. She is a member of the Italian Association for the Study of the Liver and of the European Association for the Study of the Liver (EASL) serving also as a member of the Policy and Public Health Committee of EASL. Prof Kondili has co-authored over 100 publications on hepatitis and is a frequent speaker in national and international scientific meetings.

Sonjelle Shilton joined the Foundation for Innovative New Diagnostics (FIND) in January 2017 and is currently Deputy Director, Operational Implementation Research, Foundation for Innovative New Diagnostics (FIND). Sonjelle started her career in public health as Director of Operations of HardtHaven, a community-based health outreach organization in rural Ghana. She has over fifteen years of experience in leading programmes and implementation science studies. Her time in Ghana cemented her dedication to public health approaches that are collaboratively designed and implemented with rigorous and meaningful data capture. She attained a Master of Global Public Health and the Global WACh Graduate Certificate for integrated health of Women, Adolescents and Children from the University of Washington, USA.

Maurizia R. Brunetto is Director of the Integrated Care Department of Medical Specialties and of the Liver Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses of Pisa University Hospital.  Her research activity has been focused on the study of the pathogenetic implications of hepatitis virus infection, on the analysis of factors influencing the progression of chronic hepatitis to cirrhosis and hepatocellular carcinoma and on the treatment optimization. She did seminal work in the clinic-pathologic characterization of the HBeAg negative chronic hepatitis B with the identification of Pre-core mutant and demonstrated  the clinical usefulness of HBsAg serum levels measurement in the monitoring of antiviral      therapy and identification of HBeAg negative infection with the definition of the clinical cut-off, currently suggested by the international guidelines.

Lindsey Hiebert is the Associate Director of the Coalition for Global Hepatitis Elimination. The Coalition is based at the Task Force for Global Health, an international NGO in Atlanta, United States. At the Coalition, Lindsey supports initiatives related to technical assistance, operational research, advocacy, and policy to advance hepatitis B and C elimination globally.

Dr Jess Dyson is a consultant hepatologist at the Freeman Hospital in Newcastle with a combined role as an NHS hepatologist with a major interest in clinical research based at Newcastle University. She leads the clinical service in Newcastle for patients with autoimmune liver disease including running the regional network for delivery of 2nd-line therapies in high risk primary biliary cholangitis. She is principal investigator for the UK national study for patients with autoimmune hepatitis that focuses on improving therapy for patients (UK-AIH) and a co-author on the national guidelines for primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis. She completed her PhD in 2019 investigating potential environmental risk factors related to autoimmune liver disease.

Robert Mitchell-Thain is Chief Executive Officer at the PBC Foundation and Chair of Paediatric and Rare Liver Diseases Council at the Global Liver Institute. Mitchell-Thain is a fierce patient advocate with over 20 years of international experience. A NAFLD patient himself, his main focus has been cholestatic liver disease. A member of numerous collaborative committees, lead and co-author on several patient-centric abstracts, co-author and reviewer of clinical guidelines and journal articles, he is known for challenging dogma and for a progressive approach to finding solutions in a patient-centred way, pursuing the best for all stakeholders within the community.

Jeffrey V. Lazarus (Ph.D., MIH, MA) is a Member of the EASL Policy and Public Health Committee. He holds positions as an associate research professor at the Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, where he leads the health systems research team, as Associate Professor at the Faculty of Medicine, University of Barcelona, Spain and as a senior scholar at the CUNY Graduate School of Public Health and Policy in New York City. His decade-long career as health systems, HIV, and viral hepatitis expert at WHO Europe was followed by three years (2009-2012) as a senior specialist at the Global Fund to Fight AIDS, Tuberculosis, and Malaria, three years as director of Health Systems Global (2012-15) then board chair of the foundation AFEW International (2015-18). Prof Lazarus is now Vice-Chairman of the board of the EASL International Liver Foundation, where he developed the micro-elimination approach to HCV elimination. He is also a member of the INHSU international education committee and co-chair of the HIV Outcomes Beyond Viral Suppression coalition. He is the author of more than 300 publications and his current scientific work includes leading the Hep C Free Baleares, HBV COMSAVA, and Copenhagen T'n'T studies, and the Global COVID-19 consensus statement on ending the pandemic. He is a core member of The Lancet GastroHep Commission on Viral Hepatitis, a co-author of the Lancet COVID-19 commission and a commissioner of the EASL-Lancet European Liver Commission and The Lancet-IAPAC HIV Commission. At AME/VE he is chair of the NAFLD models of care workshop, on the organizing committee of COLDA, and on the scientific committee of IVHEM.

Prof. Maja Thiele works to reduce morbidity and mortality from alcohol-related liver disease, for the benefit of an otherwise stigmatized patient group. Her research centers on the development and validation of diagnostic and prognostic biomarkers, with a particular focus on early disease detection, cost-effective referral pathways and omics technologies. Elastography expert contributor to EASL Clinical Practice Guidance, the BAVENO VII consensus statement, AASLD clinical guidance, WFUMB guideline, and The Lancet Commission on liver disease in primary care. Partner in the European research consortia GALAXY, LiverScreen, LIVERAIM, MicrobPredict and SALVE.